close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

24.54 +0.33 (+1.36%)
Streaming Delayed Price Updated: 1:40 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Viridian Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results
 
Via Benzinga
Viridian (VRDN) Q2 Net Loss Widens 55%
Via The Motley Fool
What 5 Analyst Ratings Have To Say About Viridian Therapeutics
 
Via Benzinga
Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts
 
Via Benzinga
Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views
 
Via Benzinga
In-Depth Examination Of 11 Analyst Recommendations For Viridian Therapeutics
 
Via Benzinga
Analyst Expectations For Viridian Therapeutics's Future
 
Via Benzinga
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Forecasting The Future: 13 Analyst Projections For Viridian Therapeutics
 
Via Benzinga
Critical Insights From Viridian Therapeutics Analyst Ratings: What You Need To Know
 
Via Benzinga
Decoding 6 Analyst Evaluations For Viridian Therapeutics
 
Via Benzinga
Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease
The company's drug led to an improvement in diplopia, or double vision, an area where Amgen's Tepezza hasn't worked. 
Via Investor's Business Daily
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival
The results are also promising for the next-generation version of that drug. 
Via Investor's Business Daily
Viridian Therapeutics Discloses 'Exciting' Data From Experimental Thyroid Eye Disease Candidate, Says Data Met High Bars For Efficacy, Safety
Viridian Therapeutics announced promising topline data from the THRIVE phase 3 trial of VRDN-001 (veligrotug) for active thyroid eye disease meeting all primary and secondary endpoints. Viridian plans... 
Via Benzinga
Expert Ratings For Viridian Therapeutics
 
Via Benzinga
7 Analysts Assess Viridian Therapeutics: What You Need To Know
 
Via Benzinga
Unveiling 4 Analyst Insights On Viridian Therapeutics
 
Via Benzinga
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
VRDN Stock Earnings: Viridian Therapeutics Misses EPS, Misses Revenue for Q2 2024
VRDN stock results show that Viridian Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Top 3 Health Care Stocks You May Want To Dump This Quarter
 
Via Benzinga
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. 
Via Investor's Business Daily
3 Small-Cap Stocks With Explosive 2X Growth Potential
Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024
VRDN stock results show that Viridian Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today